Clinical trials: Chronic Cough
Refractory Chronic Cough
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
- Trial name
- NCT02612623
- Testing
- Gefapixant
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cough
GSK2339345 Hypertussive Challenge Study
This study is designed to evaluate the effect of GSK2339345 relative to placebo on the number of coughs in patients with Chronic Idiopathic Cough (CIC) administered by an Aqueous Droplet Inhaler (ADI).
- Trial name
- NCT01899768
- Testing
- GSK2339345
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02233686
- Testing
- XEN-D0501
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Xention Ltd
Smoking Cessation
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
To test the hypothesis that treatment with the inverse agonist nadolol will improve smoking cessation in patients with chronic cough associated with long-term smoking, with or without airflow obstruction, including those with…
- Trial name
- NCT01825122
- Testing
- Nadolol
- Where
- 4 sites in United States
- Volunteers
- 155 people
- Sponsor
- Invion, Inc.
Refractory Chronic Cough
Treatment of Refractory Chronic Cough With PA101
This is a double-blind, randomized, placebo-controlled, 2-period crossover, 2-cohort study in adult patients with refractory chronic cough.
- Trial name
- NCT02412020
- Testing
- PA101
- Where
- 7 sites in Netherlands, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Patara Pharma
Refractory or Unexplained Chronic Cough
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic…
- Trial name
- ASPIRE (NCT06504446)
- Testing
- NOC-110
- Where
- 106 sites in United States, Belgium and 4 more
- Volunteers
- 455 people
- Sponsor
- Nocion Therapeutics
Cough, Idiopathic Pulmonary Fibrosis
Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.
- Trial name
- IPF-COMFORT (NCT05185089)
- Testing
- Orvepitant Maleate
- Where
- 37 sites in United States, Netherlands and 1 more
- Volunteers
- 80 people
- Sponsor
- Nerre Therapeutics Ltd.
Refractory Chronic Cough
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
The primary objective of this double-blind crossover study is to assess the effect of single doses of 50 mg and 300 mg gefapixant (AF-219/MK-7264) on cough reflex sensitivity to capsaicin in both healthy participants and…
- Trial name
- NCT02397460
- Testing
- Gefapixant
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Cough
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)
The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough.
- Trial name
- NCT04193176
- Testing
- Gefapixant
- Where
- 90 sites in United States, Argentina and 10 more
- Volunteers
- 376 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function
BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04454424
- Testing
- BAY1817080, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Bayer
Chronic Cough
A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)
The primary objective of this study is to evaluate the safety of two doses of gefapixant (MK-7264) in Japanese adult participants with refractory or unexplained chronic cough.
- Trial name
- NCT03696108
- Testing
- Gefapixant
- Where
- 61 sites in Japan
- Volunteers
- 175 people
- Sponsor
- Merck Sharp & Dohme LLC
Post-COVID-19 Syndrome, COVID-19
Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome
Reports of long-lasting symptoms of COVID-19 are increasing, but little is known about the prevalence of risk factors or whether it is possible to predict a prolonged course at disease onset.
- Conditions
- Post-COVID-19 Syndrome, COVID-19, Dyspnea, Fatigue
- Trial name
- NCT06437210
- Testing
- Viusid Oral Solution
- Where
- Colombia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Catalysis SL
Chronic Cough
A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration
This is a first-in-human study that will investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of HRS-2261 using a double blind, placebo controlled, randomized study design.
- Trial name
- NCT05274516
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Chronic Cough
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough
- Trial name
- NCT05392192
- Testing
- ADX-629
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Chronic Cough
Evaluation of S-600918 in Adults With Refractory Chronic Cough
The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared…
- Trial name
- NCT04110054
- Testing
- S-600918
- Where
- 136 sites in United States, Czechia and 4 more
- Volunteers
- 406 people
- Sponsor
- Shionogi
Chronic Refractory Cough
An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic…
- Trial name
- NCT01703923
- Testing
- FP01
- Where
- 8 sites in United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Avalo Therapeutics, Inc.
Endometriosis Related Pain, Overactive Bladder
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
Researchers are looking for a new way to treat people suffering either from a condition where the bladder is unable to hold urine normally (overactive bladder), or a condition in which tissue similar to the tissue that normally…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04487431
- Testing
- BAY1817080, [14C]BAY1817080
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Biological Availability
A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein
The main purpose of this study is to investigate how quickly and to what extent BAY1817080 is absorbed (taken up), distributed, metabolized (broken down) and eliminated from the body (this is called pharmacokinetics).
- Trial name
- NCT03773068
- Testing
- BAY1817080 - Formulation A, BAY1817080 - Formulation B, [13C715N]-BAY 181708 stable isotope label (SIL)
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
The study does not involve testing of a drug (no treatment intervention). The study will will use spirometry (breathing tests) in subjects of 40 years of age and older with a history of cigarette smoking with chronic bronchitis…
- Trial name
- NCT00442468
- Testing
- Non-interventional study.
- Where
- 47 sites in United States
- Volunteers
- 1,283 people
- Sponsor
- GlaxoSmithKline
Cough
Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)
This is a randomized, double-blind, placebo-controlled, crossover, single center study of SCH 486757 in subjects with chronic cough. Subjects will be randomized to receive SCH 486757 or placebo for 14 days.
- Trial name
- NCT00506987
- Testing
- SCH 486757
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC